Your browser doesn't support javascript.
Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.
Corominas, Hèctor; Castellví, Ivan; Pomar, Virginia; Antonijoan, Rosa; Mur, Isabel; Matas, Laia; Gich, Ignasi; de Benito, Natividad; Laiz, Ana; Castillo, Diego; Villamarin, Laura; Filella, David; Millán, Ana Milena; Quijada, María Ángeles; Puig, Mireia; Casademont, Jordi; Domingo, Pere.
  • Corominas H; Servei de Reumatologia, Barcelona, Catalonia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain; Unitat de Malalties infeccioses, Barcelona, Catalonia, Spain. Electronic address: Hcorominas@santpau.cat.
  • Castellví I; Servei de Reumatologia, Barcelona, Catalonia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain; Unitat de Malalties infeccioses, Barcelona, Catalonia, Spain.
  • Pomar V; Servei de Medicina Interna, Barcelona, Catalonia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain; Unitat de Malalties infeccioses, Barcelona, Catalonia, Spain.
  • Antonijoan R; Servei de Farmacología (CIBERSAM), Barcelona, Catalonia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain; Unitat de Malalties infeccioses, Barcelona, Catalonia, Spain.
  • Mur I; Servei de Medicina Interna, Barcelona, Catalonia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain.
  • Matas L; Servei de Medicina Interna, Barcelona, Catalonia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain; Unitat de Malalties infeccioses, Barcelona, Catalonia, Spain.
  • Gich I; CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Catalonia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain; Unitat de Malalties infeccioses, Barcelona, Catalonia, Spain.
  • de Benito N; Servei de Medicina Interna, Barcelona, Catalonia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain; Unitat de Malalties infeccioses, Barcelona, Catalonia, Spain.
  • Laiz A; Servei de Reumatologia, Barcelona, Catalonia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain; Unitat de Malalties infeccioses, Barcelona, Catalonia, Spain.
  • Castillo D; Servei de Respiratori, Barcelona, Catalonia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain; Unitat de Malalties infeccioses, Barcelona, Catalonia, Spain.
  • Villamarin L; Servei de Farmàcia, Barcelona, Catalonia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain.
  • Filella D; Servei de Medicina Interna, Barcelona, Catalonia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain; Unitat de Malalties infeccioses, Barcelona, Catalonia, Spain.
  • Millán AM; Servei de Reumatologia, Barcelona, Catalonia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain.
  • Quijada MÁ; Servei de Farmacología (CIBERSAM), Barcelona, Catalonia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain.
  • Puig M; Servei d'Urgències, Barcelona, Catalonia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain; Unitat de Malalties infeccioses, Barcelona, Catalonia, Spain.
  • Casademont J; Servei de Medicina Interna, Barcelona, Catalonia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain; Unitat de Malalties infeccioses, Barcelona, Catalonia, Spain.
  • Domingo P; Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain.
Clin Immunol ; 223: 108631, 2021 02.
Article in English | MEDLINE | ID: covidwho-919716
ABSTRACT
Although the starting event in COVID-19 is a viral infection some patients present with an over-exuberant inflammatory response, leading to acute lung injury (ALI) and adult respiratory distress syndrome (ARDS). Since IL-6 plays a critical role in the inflammatory response, we assessed the efficacy and safety of tocilizumab (TCZ) in this single-centre, observational study in all Covid-19 in-patient with a proven SARS-CoV-2 rapidly progressing infection to prevent ALI and ARDS. 104 patients with COVID-19 treated with TCZ had a lower mortality rate (5·8%) compared with the regional mortality rate (11%), hospitalized patient's mortality (10%), and slightly lower than hospitalized patients treated with our standard of care alone (6%). We found that TCZ rapidly decreased acute phase reactants, ferritin and liver release of proteins. D-Dimer decreased slowly. We did not observe specific safety concerns. Early administration of IL6-R antagonists in COVID-19 patients with impending hyperinflammatory response, may be safe and effective treatment to prevent, ICU admission and further complications.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Respiratory Distress Syndrome / Acute Lung Injury / Antibodies, Monoclonal, Humanized / Cytokine Release Syndrome / SARS-CoV-2 / COVID-19 / Inflammation Subject: Respiratory Distress Syndrome / Acute Lung Injury / Antibodies, Monoclonal, Humanized / Cytokine Release Syndrome / SARS-CoV-2 / COVID-19 / Inflammation Type of study: Observational study / Risk factors Language: English Journal: Clin Immunol Clinical aspect: Etiology / Therapy Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Respiratory Distress Syndrome / Acute Lung Injury / Antibodies, Monoclonal, Humanized / Cytokine Release Syndrome / SARS-CoV-2 / COVID-19 / Inflammation Subject: Respiratory Distress Syndrome / Acute Lung Injury / Antibodies, Monoclonal, Humanized / Cytokine Release Syndrome / SARS-CoV-2 / COVID-19 / Inflammation Type of study: Observational study / Risk factors Language: English Journal: Clin Immunol Clinical aspect: Etiology / Therapy Year: 2021
...